{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:01:33Z","timestamp":1784566893774,"version":"3.55.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51923-y","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:59:44Z","timestamp":1779137984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AMD3100 modulates the secretome responses of human Mesenchymal Stromal Cells but not their inhibitory effect on T cell proliferation"],"prefix":"10.1038","volume":"16","author":[{"given":"Rhett N.","family":"Parr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denton","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keenan","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawson","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenamala U.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devi","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiman","family":"Hematti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavan","family":"Chinnadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"51923_CR1","doi-asserted-by":"publisher","first-page":"204020661982938","DOI":"10.1177\/2040206619829382","volume":"27","author":"E De Clercq","year":"2019","unstructured":"De Clercq, E. Mozobil(R) (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antivir Chem. Chemother. 27, 2040206619829382. https:\/\/doi.org\/10.1177\/2040206619829382 (2019).","journal-title":"Antivir Chem. Chemother."},{"key":"51923_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrd1134","volume":"2","author":"E De Clercq","year":"2003","unstructured":"De Clercq, E. The bicyclam AMD3100 story. Nat. Rev. Drug Discov. 2, 581\u2013587. https:\/\/doi.org\/10.1038\/nrd1134 (2003).","journal-title":"Nat. Rev. Drug Discov"},{"key":"51923_CR3","doi-asserted-by":"publisher","unstructured":"De Clercq, E. AMD3100\/CXCR4 Inhibitor. Front. Immunol. 6 https:\/\/doi.org\/10.3389\/fimmu.2015.00276 (2015).","DOI":"10.3389\/fimmu.2015.00276"},{"key":"51923_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000315736","volume":"78","author":"M Brave","year":"2010","unstructured":"Brave, M. et al. FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78, 282\u2013288. https:\/\/doi.org\/10.1159\/000315736 (2010).","journal-title":"Oncology"},{"key":"51923_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/MOH.0000000000000200","volume":"23","author":"YM Bilgin","year":"2016","unstructured":"Bilgin, Y. M. & de Greef, G. E. Plerixafor for stem cell mobilization: the current status. Curr. Opin. Hematol. 23, 67\u201371. https:\/\/doi.org\/10.1097\/MOH.0000000000000200 (2016).","journal-title":"Curr. Opin. Hematol."},{"key":"51923_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1537-2995.2011.03349.x","volume":"52","author":"E Jantunen","year":"2012","unstructured":"Jantunen, E. & Lemoli, R. M. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 52, 906\u2013914. https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03349.x (2012).","journal-title":"Transfusion"},{"key":"51923_CR7","doi-asserted-by":"publisher","first-page":"103830","DOI":"10.1016\/j.transci.2023.103830","volume":"62","author":"F Lanza","year":"2023","unstructured":"Lanza, F., Marchetti, M. & Zannetti, B. A. Overview on novel strategies and current guidelines for hematopoietic stem cell mobilisation and collection. Transfus. Apher Sci. 62, 103830. https:\/\/doi.org\/10.1016\/j.transci.2023.103830 (2023).","journal-title":"Transfus. Apher Sci."},{"key":"51923_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0014-5793(02)03143-5","volume":"527","author":"S Hatse","year":"2002","unstructured":"Hatse, S., Princen, K., Bridger, G., De Clercq, E. & Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527, 255\u2013262. https:\/\/doi.org\/10.1016\/S0014-5793(02)03143-5 (2002).","journal-title":"FEBS Lett."},{"key":"51923_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMoa1808575","volume":"380","author":"DH McDermott","year":"2019","unstructured":"McDermott, D. H. et al. Plerixafor for the Treatment of WHIM Syndrome. N. Engl. J. Med. 380, 163\u2013170. https:\/\/doi.org\/10.1056\/NEJMoa1808575 (2019).","journal-title":"N. Engl. J. Med."},{"key":"51923_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1667\/rr2886.1","volume":"178","author":"JH Kim","year":"2012","unstructured":"Kim, J. H., Kolozsvary, A., Jenrow, K. A., Brown, S. L. & Plerixafor a CXCR4 antagonist, mitigates skin radiation-induced injury in mice. Radiat. Res. 178, 202\u2013206. https:\/\/doi.org\/10.1667\/rr2886.1 (2012).","journal-title":"Radiat. Res."},{"key":"51923_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.exphem.2012.01.005","volume":"40","author":"VK Singh","year":"2012","unstructured":"Singh, V. K. et al. alpha-Tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation-induced gastrointestinal injury in mice. Exp. Hematol. 40, 407\u2013417. https:\/\/doi.org\/10.1016\/j.exphem.2012.01.005 (2012).","journal-title":"Exp. Hematol."},{"key":"51923_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ajpath.2023.04.013","volume":"193","author":"M Montesinos-Rongen","year":"2023","unstructured":"Montesinos-Rongen, M. et al. AMD3100-Mediated CXCR4 Inhibition Impairs Development of Primary Lymphoma of the Central Nervous System. Am. J. Pathol. 193, 1101\u20131115. https:\/\/doi.org\/10.1016\/j.ajpath.2023.04.013 (2023).","journal-title":"Am. J. Pathol."},{"key":"51923_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1172\/JCI40283","volume":"120","author":"M Kioi","year":"2010","unstructured":"Kioi, M. et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Investig. 120, 694\u2013705. https:\/\/doi.org\/10.1172\/JCI40283 (2010).","journal-title":"J. Clin. Investig."},{"key":"51923_CR14","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.radonc.2013.06.019","volume":"108","author":"N Chaudary","year":"2013","unstructured":"Chaudary, N., Mujcic, H., Wouters, B. G. & Hill, R. P. Hypoxia and metastasis in an orthotopic cervix cancer xenograft model. Radiother Oncol. 108, 506\u2013510. https:\/\/doi.org\/10.1016\/j.radonc.2013.06.019 (2013).","journal-title":"Radiother Oncol."},{"key":"51923_CR15","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.1038\/ncomms9494","volume":"6","author":"H Liu","year":"2015","unstructured":"Liu, H., Liu, Y., Liu, W., Zhang, W. & Xu, J. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat. Commun. 6, 8494. https:\/\/doi.org\/10.1038\/ncomms9494 (2015).","journal-title":"Nat. Commun."},{"key":"51923_CR16","doi-asserted-by":"publisher","first-page":"105406","DOI":"10.1016\/j.jsbmb.2019.105406","volume":"192","author":"YG Jang","year":"2019","unstructured":"Jang, Y. G., Go, R. E., Hwang, K. A. & Choi, K. C. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway. J. Steroid Biochem. Mol. Biol. 192, 105406. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105406 (2019).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"51923_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.canlet.2018.01.009","volume":"418","author":"KX Zhou","year":"2018","unstructured":"Zhou, K. X. et al. CXCR4 antagonist AMD3100 enhances the response of MDA-MB-231 triple-negative breast cancer cells to ionizing radiation. Cancer Lett. 418, 196\u2013203. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.009 (2018).","journal-title":"Cancer Lett."},{"key":"51923_CR18","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1158\/1078-0432.CCR-05-1940","volume":"12","author":"S Scala","year":"2006","unstructured":"Scala, S. et al. Human melanoma metastases express functional CXCR4. Clin. cancer research: official J. Am. Association Cancer Res. 12, 2427\u20132433. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1940 (2006).","journal-title":"Clin. cancer research: official J. Am. Association Cancer Res."},{"key":"51923_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1078-0432.CCR-15-3140","volume":"23","author":"R Mustafi","year":"2017","unstructured":"Mustafi, R. et al. ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet-associated Colon Cancer. Clin. cancer research: official J. Am. Association Cancer Res. 23, 549\u2013561. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3140 (2017).","journal-title":"Clin. cancer research: official J. Am. Association Cancer Res."},{"key":"51923_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-016-0050-5","volume":"5","author":"T Liu","year":"2015","unstructured":"Liu, T., Li, X., You, S., Bhuyan, S. S. & Dong, L. Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice. Exp. Hematol. Oncol. 5, 19. https:\/\/doi.org\/10.1186\/s40164-016-0050-5 (2015).","journal-title":"Exp. Hematol. Oncol."},{"key":"51923_CR21","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1096\/fj.201802067RR","volume":"33","author":"Y Zeng","year":"2019","unstructured":"Zeng, Y. et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 33, 6596\u20136608. https:\/\/doi.org\/10.1096\/fj.201802067RR (2019).","journal-title":"FASEB J."},{"key":"51923_CR22","doi-asserted-by":"publisher","first-page":"28960","DOI":"10.1073\/pnas.2013644117","volume":"117","author":"D Biasci","year":"2020","unstructured":"Biasci, D. et al. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc. Natl. Acad. Sci. U S A. 117, 28960\u201328970. https:\/\/doi.org\/10.1073\/pnas.2013644117 (2020).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"51923_CR23","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.4049\/jimmunol.167.8.4686","volume":"167","author":"P Matthys","year":"2001","unstructured":"Matthys, P. et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J. Immunol. 167, 4686\u20134692. https:\/\/doi.org\/10.4049\/jimmunol.167.8.4686 (2001).","journal-title":"J. Immunol."},{"key":"51923_CR24","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.4110\/in.2024.24.e25","volume":"24","author":"SH Jang","year":"2024","unstructured":"Jang, S. H. et al. Mitochondria Activity and CXCR4 Collaboratively Promote the Differentiation of CD11c(+) B Cells Induced by TLR9 in Lupus. Immune Netw. 24, e25. https:\/\/doi.org\/10.4110\/in.2024.24.e25 (2024).","journal-title":"Immune Netw."},{"key":"51923_CR25","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1182\/blood-2011-06-359331","volume":"118","author":"LS Kean","year":"2011","unstructured":"Kean, L. S. et al. Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood 118, 6580\u20136590. https:\/\/doi.org\/10.1182\/blood-2011-06-359331 (2011).","journal-title":"Blood"},{"key":"51923_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41598-017-00141-8","volume":"7","author":"JM Liu","year":"2017","unstructured":"Liu, J. M. et al. AMD3100 inhibits the migration and differentiation of neural stem cells after spinal cord injury. Sci. Rep. 7, 64. https:\/\/doi.org\/10.1038\/s41598-017-00141-8 (2017).","journal-title":"Sci. Rep."},{"key":"51923_CR27","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/eji.201445245","volume":"45","author":"Q Liu","year":"2015","unstructured":"Liu, Q. et al. CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in mice. Eur. J. Immunol. 45, 1855\u20131867. https:\/\/doi.org\/10.1002\/eji.201445245 (2015).","journal-title":"Eur. J. Immunol."},{"key":"51923_CR28","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.3892\/mmr.2020.11432","volume":"22","author":"C Jiang","year":"2020","unstructured":"Jiang, C. et al. AMD3100 and SDF\u20131 regulate cellular functions of endothelial progenitor cells and accelerate endothelial regeneration in a rat carotid artery injury model. Mol. Med. Rep. 22, 3201\u20133212. https:\/\/doi.org\/10.3892\/mmr.2020.11432 (2020).","journal-title":"Mol. Med. Rep."},{"key":"51923_CR29","doi-asserted-by":"publisher","first-page":"e27282","DOI":"10.1371\/journal.pone.0027282","volume":"6","author":"XM Xia","year":"2011","unstructured":"Xia, X. M. et al. CXCR4 antagonist AMD3100 modulates claudin expression and intestinal barrier function in experimental colitis. PloS one. 6, e27282. https:\/\/doi.org\/10.1371\/journal.pone.0027282 (2011).","journal-title":"PloS one"},{"key":"51923_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.stem.2021.09.006","volume":"28","author":"M Krampera","year":"2021","unstructured":"Krampera, M. & Le Blanc, K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell. stem cell. 28, 1708\u20131725. https:\/\/doi.org\/10.1016\/j.stem.2021.09.006 (2021).","journal-title":"Cell. stem cell."},{"key":"51923_CR31","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.stem.2025.05.008","volume":"32","author":"S Viswanathan","year":"2025","unstructured":"Viswanathan, S. & Galipeau, J. Hallmarks of MSCs: Key quality attributes for pharmacology and clinical use. Cell. stem cell. 32, 878\u2013894. https:\/\/doi.org\/10.1016\/j.stem.2025.05.008 (2025).","journal-title":"Cell. stem cell."},{"key":"51923_CR32","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","volume":"15","author":"M Krampera","year":"2013","unstructured":"Krampera, M. et al. Immunological characterization of multipotent mesenchymal stromal cells\u2013The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 15, 1054\u20131061. https:\/\/doi.org\/10.1016\/j.jcyt.2013.02.010 (2013).","journal-title":"Cytotherapy"},{"key":"51923_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315\u2013317. https:\/\/doi.org\/10.1080\/14653240600855905 (2006).","journal-title":"Cytotherapy"},{"key":"51923_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jcyt.2024.10.008","volume":"27","author":"L Renesme","year":"2025","unstructured":"Renesme, L. et al. Delphi-driven consensus definition for mesenchymal stromal cells and clinical reporting guidelines for mesenchymal stromal cell-based therapeutics. Cytotherapy 27, 146\u2013168. https:\/\/doi.org\/10.1016\/j.jcyt.2024.10.008 (2025).","journal-title":"Cytotherapy"},{"key":"51923_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/TP.0b013e3181938998","volume":"87","author":"K Bartsch","year":"2009","unstructured":"Bartsch, K. et al. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. Transplantation 87, 217\u2013221. https:\/\/doi.org\/10.1097\/TP.0b013e3181938998 (2009).","journal-title":"Transplantation"},{"key":"51923_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.exphem.2005.02.004","volume":"33","author":"K Rieger","year":"2005","unstructured":"Rieger, K. et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp. Hematol. 33, 605\u2013611. https:\/\/doi.org\/10.1016\/j.exphem.2005.02.004 (2005).","journal-title":"Exp. Hematol."},{"key":"51923_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1532\/IJH97.A10505","volume":"82","author":"J Wang","year":"2005","unstructured":"Wang, J., Liu, K. & Lu, D. P. Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin. Int. J. Hematol. 82, 152\u2013158. https:\/\/doi.org\/10.1532\/IJH97.A10505 (2005).","journal-title":"Int. J. Hematol."},{"key":"51923_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.bbmt.2015.01.014","volume":"21","author":"IB Copland","year":"2015","unstructured":"Copland, I. B., Qayed, M., Garcia, M. A., Galipeau, J. & Waller, E. K. Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity. Biology blood marrow transplantation: J. Am. Soc. Blood Marrow Transplantation. 21, 934\u2013940. https:\/\/doi.org\/10.1016\/j.bbmt.2015.01.014 (2015).","journal-title":"Biology blood marrow transplantation: J. Am. Soc. Blood Marrow Transplantation"},{"key":"51923_CR39","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/stmcls\/sxae040","volume":"42","author":"TU Faircloth","year":"2024","unstructured":"Faircloth, T. U. et al. Vascular endothelial growth factor secretion and immunosuppression are distinct potency mechanisms of human bone marrow mesenchymal stromal cells. Stem cells. 42, 736\u2013751. https:\/\/doi.org\/10.1093\/stmcls\/sxae040 (2024).","journal-title":"Stem cells"},{"key":"51923_CR40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/stcltm\/szac050","volume":"11","author":"AJ Lipat","year":"2022","unstructured":"Lipat, A. J. et al. Chemokine Assay Matrix Defines the Potency of Human Bone Marrow Mesenchymal Stromal Cells. Stem Cells Transl Med. 11, 971\u2013986. https:\/\/doi.org\/10.1093\/stcltm\/szac050 (2022).","journal-title":"Stem Cells Transl Med."},{"key":"51923_CR41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","volume":"18","author":"J Galipeau","year":"2016","unstructured":"Galipeau, J. et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 18, 151\u2013159 (2016).","journal-title":"Cytotherapy"},{"key":"51923_CR42","doi-asserted-by":"publisher","first-page":"972095","DOI":"10.3389\/fimmu.2022.972095","volume":"13","author":"KP Robb","year":"2022","unstructured":"Robb, K. P., Audet, J., Gandhi, R. & Viswanathan, S. Putative critical quality attribute matrix identifies mesenchymal stromal cells with potent immunomodulatory and angiogenic fitness ranges in response to culture process parameters. Front. Immunol. 13, 972095. https:\/\/doi.org\/10.3389\/fimmu.2022.972095 (2022).","journal-title":"Front. Immunol."},{"key":"51923_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-031-30040-0_6","volume":"1420","author":"R Chinnadurai","year":"2023","unstructured":"Chinnadurai, R. Advanced Technologies for Potency Assay Measurement. Adv. Exp. Med. Biol. 1420, 81\u201395. https:\/\/doi.org\/10.1007\/978-3-031-30040-0_6 (2023).","journal-title":"Adv. Exp. Med. Biol."},{"key":"51923_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/stmcls\/sxac064","author":"AP Porter","year":"2022","unstructured":"Porter, A. P. et al. Conglomeration of T and B Cell Matrix Responses Determines the Potency of Human Bone Marrow Mesenchymal Stromal Cells. Stem cells. https:\/\/doi.org\/10.1093\/stmcls\/sxac064 (2022).","journal-title":"Stem cells"},{"key":"51923_CR45","doi-asserted-by":"publisher","first-page":"101988","DOI":"10.1016\/j.jcyt.2025.09.011","volume":"28","author":"Y Shimazu","year":"2026","unstructured":"Shimazu, Y. et al. Comparison of stem cell mobilization methods in multiple myeloma. Cytotherapy 28, 101988. https:\/\/doi.org\/10.1016\/j.jcyt.2025.09.011 (2026).","journal-title":"Cytotherapy"},{"key":"51923_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13287-022-02802-6","volume":"13","author":"C Luo","year":"2022","unstructured":"Luo, C. et al. Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials. Stem Cell. Res. Ther. 13, 123. https:\/\/doi.org\/10.1186\/s13287-022-02802-6 (2022).","journal-title":"Stem Cell. Res. Ther."},{"key":"51923_CR47","doi-asserted-by":"publisher","first-page":"2329140","DOI":"10.1080\/07853890.2024.2329140","volume":"56","author":"Y Li","year":"2024","unstructured":"Li, Y., Qiu, X., Lei, Y. & Zhou, R. G-CSF\u2009+\u2009plerixafor versus G-CSF alone mobilized hematopoietic stem cells in patients with multiple myeloma and lymphoma: a systematic review and meta-analysis. Ann. Med. 56, 2329140. https:\/\/doi.org\/10.1080\/07853890.2024.2329140 (2024).","journal-title":"Ann. Med."},{"key":"51923_CR48","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/trf.17755","volume":"64","author":"E Jantunen","year":"2024","unstructured":"Jantunen, E., Turunen, A., Varmavuo, V. & Partanen, A. Impact of plerixafor use in the mobilization of blood grafts for autologous hematopoietic cell transplantation. Transfusion 64, 742\u2013750. https:\/\/doi.org\/10.1111\/trf.17755 (2024).","journal-title":"Transfusion"},{"key":"51923_CR49","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1007\/s00277-024-05935-1","volume":"103","author":"D Cancilla","year":"2024","unstructured":"Cancilla, D. et al. Analysis of a plerixafor sparing mobilization regimen for autologous hematopoietic cell transplant in multiple myeloma. Ann. Hematol. 103, 6027\u20136030. https:\/\/doi.org\/10.1007\/s00277-024-05935-1 (2024).","journal-title":"Ann. Hematol."},{"key":"51923_CR50","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/10781552241247472","volume":"30","author":"L Dietz","year":"2024","unstructured":"Dietz, L., Marini, J., Hashmi, H. & McGann, M. A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection. J. Oncol. Pharm. Pract. 30, 1073\u20131077. https:\/\/doi.org\/10.1177\/10781552241247472 (2024).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"51923_CR51","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1182\/blood-2005-09-3592","volume":"107","author":"A Larochelle","year":"2006","unstructured":"Larochelle, A. et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107, 3772\u20133778. https:\/\/doi.org\/10.1182\/blood-2005-09-3592 (2006).","journal-title":"Blood"},{"key":"51923_CR52","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1182\/blood-2016-09-739722","volume":"129","author":"MA Schroeder","year":"2017","unstructured":"Schroeder, M. A. et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood 129, 2680\u20132692. https:\/\/doi.org\/10.1182\/blood-2016-09-739722 (2017).","journal-title":"Blood"},{"key":"51923_CR53","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/bmt.2014.330","volume":"50","author":"F Saraceni","year":"2015","unstructured":"Saraceni, F., Shem-Tov, N., Olivieri, A. & Nagler, A. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant. 50, 886\u2013891. https:\/\/doi.org\/10.1038\/bmt.2014.330 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"51923_CR54","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jcyt.2013.03.013","volume":"15","author":"B Gaugler","year":"2013","unstructured":"Gaugler, B. et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy 15, 861\u2013868. https:\/\/doi.org\/10.1016\/j.jcyt.2013.03.013 (2013).","journal-title":"Cytotherapy"},{"key":"51923_CR55","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1089\/scd.2006.0087","volume":"16","author":"Y Gazitt","year":"2007","unstructured":"Gazitt, Y., Freytes, C. O., Akay, C., Badel, K. & Calandra, G. Improved mobilization of peripheral blood CD34\u2009+\u2009cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin\u2019s lymphoma patients. Stem. Cells. Dev. 16, 657\u2013666. https:\/\/doi.org\/10.1089\/scd.2006.0087 (2007).","journal-title":"Stem. Cells. Dev."},{"key":"51923_CR56","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/j.1537-2995.2011.03525.x","volume":"52","author":"V Varmavuo","year":"2012","unstructured":"Varmavuo, V., Mantymaa, P., Kuittinen, T., Nousiainen, T. & Jantunen, E. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin\u2019s lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor. Transfusion 52, 1785\u20131791. https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03525.x (2012).","journal-title":"Transfusion"},{"key":"51923_CR57","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1600-0609.2012.01794.x","volume":"89","author":"V Varmavuo","year":"2012","unstructured":"Varmavuo, V. et al. Blood graft composition after plerixafor injection in patients with NHL. Eur. J. Haematol. 89, 128\u2013135. https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01794.x (2012).","journal-title":"Eur. J. Haematol."},{"key":"51923_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.v98.3.579","volume":"98","author":"LF Porrata","year":"2001","unstructured":"Porrata, L. F. et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98, 579\u2013585. https:\/\/doi.org\/10.1182\/blood.v98.3.579 (2001).","journal-title":"Blood"},{"key":"51923_CR59","doi-asserted-by":"publisher","unstructured":"Porrata, L. F. The Impact of Infused Autograft Absolute Numbers of Immune Effector Cells on Survival Post-Autologous Stem Cell Transplantation. Cells 11, (2022). https:\/\/doi.org\/10.3390\/cells11142197","DOI":"10.3390\/cells11142197"},{"key":"51923_CR60","doi-asserted-by":"publisher","unstructured":"Partanen, A. et al. Predictive Factors for Early Immune Recovery in NHL Patients after Autologous Transplantation: A Multicenter Prospective Study. Cancers (Basel). 16 https:\/\/doi.org\/10.3390\/cancers16142550 (2024).","DOI":"10.3390\/cancers16142550"},{"key":"51923_CR61","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12967-021-02822-5","volume":"19","author":"N Cuesta-Gomez","year":"2021","unstructured":"Cuesta-Gomez, N., Graham, G. J. & Campbell, J. D. M. Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells. J. Transl Med. 19, 156. https:\/\/doi.org\/10.1186\/s12967-021-02822-5 (2021).","journal-title":"J. Transl Med."},{"key":"51923_CR62","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/stem.3380","volume":"39","author":"J Galipeau","year":"2021","unstructured":"Galipeau, J. Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity. Stem cells. 39, 1145\u20131154. https:\/\/doi.org\/10.1002\/stem.3380 (2021).","journal-title":"Stem cells"},{"key":"51923_CR63","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.it.2017.08.004","volume":"38","author":"P Lopez-Cotarelo","year":"2017","unstructured":"Lopez-Cotarelo, P., Gomez-Moreira, C., Criado-Garcia, O., Sanchez, L. & Rodriguez-Fernandez, J. L. Beyond Chemoattraction: Multifunctionality of Chemokine Receptors in Leukocytes. Trends Immunol. 38, 927\u2013941. https:\/\/doi.org\/10.1016\/j.it.2017.08.004 (2017).","journal-title":"Trends Immunol."},{"key":"51923_CR64","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/febs.14466","volume":"285","author":"CE Hughes","year":"2018","unstructured":"Hughes, C. E. & Nibbs, R. J. B. A guide to chemokines and their receptors. FEBS J. 285, 2944\u20132971. https:\/\/doi.org\/10.1111\/febs.14466 (2018).","journal-title":"FEBS J."},{"key":"51923_CR65","doi-asserted-by":"publisher","unstructured":"Brylka, L. J. & Schinke, T. Chemokines in Physiological and Pathological Bone Remodeling. Front. Immunol. 10 https:\/\/doi.org\/10.3389\/fimmu.2019.02182 (2019).","DOI":"10.3389\/fimmu.2019.02182"},{"key":"51923_CR66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000353317","volume":"99","author":"D Bosisio","year":"2014","unstructured":"Bosisio, D., Salvi, V., Gagliostro, V. & Sozzani, S. Angiogenic and antiangiogenic chemokines. Chem. Immunol. Allergy. 99, 89\u2013104. https:\/\/doi.org\/10.1159\/000353317 (2014).","journal-title":"Chem. Immunol. Allergy"},{"key":"51923_CR67","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/blood-2004-02-0526","volume":"104","author":"RF Wynn","year":"2004","unstructured":"Wynn, R. F. et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104, 2643\u20132645. https:\/\/doi.org\/10.1182\/blood-2004-02-0526 (2004).","journal-title":"Blood"},{"key":"51923_CR68","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2004-09-3507","volume":"106","author":"V Sordi","year":"2005","unstructured":"Sordi, V. et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 106, 419\u2013427. https:\/\/doi.org\/10.1182\/blood-2004-09-3507 (2005).","journal-title":"Blood"},{"key":"51923_CR69","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1634\/stemcells.2005-0319","volume":"24","author":"M Honczarenko","year":"2006","unstructured":"Honczarenko, M. et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem cells. 24, 1030\u20131041. https:\/\/doi.org\/10.1634\/stemcells.2005-0319 (2006).","journal-title":"Stem cells"},{"key":"51923_CR70","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3324\/haematol.10669","volume":"92","author":"M Shi","year":"2007","unstructured":"Shi, M. et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD\/SCID mice. Haematologica 92, 897\u2013904. https:\/\/doi.org\/10.3324\/haematol.10669 (2007).","journal-title":"Haematologica"},{"key":"51923_CR71","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.it.2008.02.011","volume":"29","author":"E Valk","year":"2008","unstructured":"Valk, E., Rudd, C. E. & Schneider, H. CTLA-4 trafficking and surface expression. Trends Immunol. 29, 272\u2013279. https:\/\/doi.org\/10.1016\/j.it.2008.02.011 (2008).","journal-title":"Trends Immunol."},{"key":"51923_CR72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbmt.2008.10.018","volume":"15","author":"DA Stewart","year":"2009","unstructured":"Stewart, D. A., Smith, C., MacFarland, R. & Calandra, G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biology blood marrow transplantation: J. Am. Soc. Blood Marrow Transplantation. 15, 39\u201346. https:\/\/doi.org\/10.1016\/j.bbmt.2008.10.018 (2009).","journal-title":"Biology blood marrow transplantation: J. Am. Soc. Blood Marrow Transplantation"},{"key":"51923_CR73","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jcyt.2025.01.005","volume":"27","author":"KL Blanc","year":"2025","unstructured":"Blanc, K. L. et al. ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells. Cytotherapy 27, 413\u2013416. https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.005 (2025).","journal-title":"Cytotherapy"},{"key":"51923_CR74","doi-asserted-by":"publisher","first-page":"1192636","DOI":"10.3389\/fimmu.2023.1192636","volume":"14","author":"R Chinnadurai","year":"2023","unstructured":"Chinnadurai, R., Viswanathan, S., Moll, G. & Editorial Next generation MSC therapy manufacturing, potency and mechanism of action analysis. Front. Immunol. 14, 1192636. https:\/\/doi.org\/10.3389\/fimmu.2023.1192636 (2023).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51923-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51923-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51923-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:02:20Z","timestamp":1784563340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51923-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51923"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51923-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22602"}}